Vera Therapeutics Completes Enrollment For Primary Endpoint In Pivotal Phase 3 ORIGIN 3 Trial Of Atacicept In IgAN
Vera Therapeutics Completes Enrollment For Primary Endpoint In Pivotal Phase 3 ORIGIN 3 Trial Of Atacicept In IgAN
-
On track to announce topline results from ORIGIN 3 trial in Q2 2025
- Expect to present 96-week data from ORIGIN Phase 2b clinical trial of atacicept in IgAN in Q4 2024
- 有望在2025年第二季度公佈ORIGIN 3試驗的頭條結果
- 預計將在2024年第四季度公佈ORIGIN在iGaN中對阿他西普進行20期臨床試驗的96週數據
BRISBANE, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has completed enrollment ahead of schedule for the primary endpoint in the pivotal Phase 3 ORIGIN 3 trial of atacicept in patients with IgAN. The enrollment of 200 participants in this initial cohort of the trial will provide data for the 36-week UPCR primary efficacy endpoint, supporting the subsequent submission for regulatory approval.
加利福尼亞州布里斯班，2024年9月12日（GLOBE NEWSWIRE）——專注於爲嚴重免疫性疾病患者開發和商業化變革性療法的臨床後期生物技術公司Vera Therapeutics, Inc.（納斯達克股票代碼：VERA）今天宣佈，它已提前完成針對iGaN患者的阿他西普的關鍵3期ORIGIN 3期試驗主要終點的註冊。該試驗的初始隊列中有200名參與者入組，將爲36周的UPCR主要療效終點提供數據，爲隨後提交監管機構批准提供支持。
譯文內容由第三人軟體翻譯。